Krystal Biotech sells VYJUVEK, a topical gene therapy for dystrophic epidermolysis bullosa, a rare skin disease, and its gross margin of 94.6% and operating margin of 49.0% show how much of each dollar of sales drops through once the product is on the market. Its moat is regulatory and manufacturing rather than patent-only: the drug is delivered as a gel applied to wounds, so it avoids the systemic dosing and manufacturing complexity that has slowed most other gene therapies. Revenue growth of 24.1% and a 20.1% return on equity mean the business is compounding, while the valuation (41.4x trailing earnings, 46.9x forward) leaves little room for a stumble in launch execution or pipeline news. Worth a deeper look to see how quickly new indications and the ex-US rollout can keep that growth rate going, and how much of the current multiple is already pricing it in. The stock is not in any major index, which may matter for flows if the company keeps scaling.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 19 Oct 2026, 18:04 CEST | Rating | Overvalued | first publication | $317 |
| 19 Oct 2026, 18:04 CEST | Fair value | $153 | $251 | $317 |
| 11 Oct 2026, 00:00 CEST | Fair value | $251 | $190 | $332 |
| 10 Oct 2026, 00:00 CEST | ACCE price target | $295 | first publication | $327 |
| 7 Oct 2026, 00:00 CEST | Fair value | $190 | $183 | $335 |
| 30 Sept 2026, 00:00 CEST | Fair value | $183 | $190 | $337 |
| 16 Sept 2026, 00:00 CEST | Fair value | $190 | $195 | $340 |
| 11 Sept 2026, 00:00 CEST | Fair value | $195 | $197 | $348 |
| 8 Sept 2026, 00:00 CEST | Fair value | $197 | $200 | $358 |
| 5 Sept 2026, 00:00 CEST | Fair value | $200 | $203 | $371 |
Answered from Krystal Biotech Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech Inc. Common Stock | $311.50 | $153 | 104% above | 39.0x | 20.1% | 95 | 71 |
| TWST Twist Bioscience Corporation Common Stock | $135.47 | - | - | - | -29.6% | 43 | 51 |
| CORT Corcept Therapeutics Incorporated Common Stock | $107.50 | $38 | 180% above | 190.8x | 8.2% | 75 | 73 |
| PCVX Vaxcyte Inc. Common Stock | $62.85 | - | - | - | -36.5% | 31 | 36 |
| MDGL Madrigal Pharmaceuticals Inc. Common Stock | $453.34 | - | - | - | -53.3% | 43 | 40 |
| APGE Apogee Therapeutics Inc. Common Stock | $135.07 | - | - | - | -32.5% | 31 | 40 |
| BMRN BioMarin Pharmaceutical Inc. Common Stock | $56.63 | $45 | 25% above | 151.2x | 1.2% | 63 | 56 |
Where KRYS ranks against its sector peers on each metric.